163 related articles for article (PubMed ID: 25823654)
1. Up-regulation of CD44 in the development of metastasis, recurrence and drug resistance of ovarian cancer.
Gao Y; Foster R; Yang X; Feng Y; Shen JK; Mankin HJ; Hornicek FJ; Amiji MM; Duan Z
Oncotarget; 2015 Apr; 6(11):9313-26. PubMed ID: 25823654
[TBL] [Abstract][Full Text] [Related]
2. Identification of the IGF1/PI3K/NF κB/ERK gene signalling networks associated with chemotherapy resistance and treatment response in high-grade serous epithelial ovarian cancer.
Koti M; Gooding RJ; Nuin P; Haslehurst A; Crane C; Weberpals J; Childs T; Bryson P; Dharsee M; Evans K; Feilotter HE; Park PC; Squire JA
BMC Cancer; 2013 Nov; 13():549. PubMed ID: 24237932
[TBL] [Abstract][Full Text] [Related]
3. SSRI use and clinical outcomes in epithelial ovarian cancer.
Christensen DK; Armaiz-Pena GN; Ramirez E; Matsuo K; Zimmerman B; Zand B; Shinn E; Goodheart MJ; Bender D; Thaker PH; Ahmed A; Penedo FJ; DeGeest K; Mendez L; Domann F; Sood AK; Lutgendorf SK
Oncotarget; 2016 May; 7(22):33179-91. PubMed ID: 27121207
[TBL] [Abstract][Full Text] [Related]
4. A novel monoclonal antibody KMP1 has potential antitumor activity of bladder cancer by blocking CD44 in vivo and in vitro.
Chen Y; Wang H; Zuo Y; Li N; Ding M; Li C
Cancer Med; 2018 May; 7(5):2064-2077. PubMed ID: 29577645
[TBL] [Abstract][Full Text] [Related]
5. CRISPR-Cas9-Mediated Silencing of CD44 in Human Highly Metastatic Osteosarcoma Cells.
Liu T; Yan Z; Liu Y; Choy E; Hornicek FJ; Mankin H; Duan Z
Cell Physiol Biochem; 2018; 46(3):1218-1230. PubMed ID: 29672299
[TBL] [Abstract][Full Text] [Related]
6. Investigating the mechanisms of drug resistance and prognosis in ovarian cancer using single-cell RNA sequencing and bulk RNA sequencing.
Liu P; Liu J; Liu J; Yu X
Aging (Albany NY); 2024 Mar; 16(5):4736-4758. PubMed ID: 38461424
[TBL] [Abstract][Full Text] [Related]
7. A distinct pre-existing inflammatory tumour microenvironment is associated with chemotherapy resistance in high-grade serous epithelial ovarian cancer.
Koti M; Siu A; Clément I; Bidarimath M; Turashvili G; Edwards A; Rahimi K; Mes-Masson AM; Squire JA
Br J Cancer; 2015 Mar; 112(7):1215-22. PubMed ID: 25826225
[TBL] [Abstract][Full Text] [Related]
8. HOTAIR is a potential target for the treatment of cisplatin‑resistant ovarian cancer.
Wang Y; Wang H; Song T; Zou Y; Jiang J; Fang L; Li P
Mol Med Rep; 2015 Aug; 12(2):2211-6. PubMed ID: 25824616
[TBL] [Abstract][Full Text] [Related]
9. Clinical relevance of CD44 surface expression in advanced stage serous epithelial ovarian cancer: a prospective study.
Elzarkaa AA; Sabaa BE; Abdelkhalik D; Mansour H; Melis M; Shaalan W; Farouk M; Malik E; Soliman AA
J Cancer Res Clin Oncol; 2016 May; 142(5):949-58. PubMed ID: 26762850
[TBL] [Abstract][Full Text] [Related]
10. Innovative therapy of ovarian cancer based on overexpression of CD44 receptor.
Bukowska B; Marczak A
Ginekol Pol; 2015 May; 86(5):388-91. PubMed ID: 26117979
[TBL] [Abstract][Full Text] [Related]
11. CD44 increases the efficiency of distant metastasis of breast cancer.
McFarlane S; Coulter JA; Tibbits P; O'Grady A; McFarlane C; Montgomery N; Hill A; McCarthy HO; Young LS; Kay EW; Isacke CM; Waugh DJ
Oncotarget; 2015 May; 6(13):11465-76. PubMed ID: 25888636
[TBL] [Abstract][Full Text] [Related]
12. Profiling cancer gene mutations in longitudinal epithelial ovarian cancer biopsies by targeted next-generation sequencing: a retrospective study.
Beltrame L; Di Marino M; Fruscio R; Calura E; Chapman B; Clivio L; Sina F; Mele C; Iatropoulos P; Grassi T; Fotia V; Romualdi C; Martini P; Noris M; Paracchini L; Craparotta I; Petrillo M; Milani R; Perego P; Ravaggi A; Zambelli A; Ronchetti E; D'Incalci M; Marchini S
Ann Oncol; 2015 Jul; 26(7):1363-71. PubMed ID: 25846551
[TBL] [Abstract][Full Text] [Related]
13. CD44 expression contributes to trastuzumab resistance in HER2-positive breast cancer cells.
Boulbes DR; Chauhan GB; Jin Q; Bartholomeusz C; Esteva FJ
Breast Cancer Res Treat; 2015 Jun; 151(3):501-13. PubMed ID: 25971596
[TBL] [Abstract][Full Text] [Related]
14. MicroRNA-9 promotes tumorigenesis and mediates sensitivity to cisplatin in primary epithelial ovarian cancer cells.
Zhao HM; Wei W; Sun YH; Gao JH; Wang Q; Zheng JH
Tumour Biol; 2015 Sep; 36(9):6867-73. PubMed ID: 25846738
[TBL] [Abstract][Full Text] [Related]
15. Retraction note: Investigation of the hub genes and related mechanism in ovarian cancer via bioinformatics analysis.
Fu LJ; Wang B
J Ovarian Res; 2015 Mar; 8(1):15. PubMed ID: 25825142
[TBL] [Abstract][Full Text] [Related]
16. The expression of DBC1/CCAR2 is associated with poor prognosis of ovarian carcinoma.
Cho D; Park H; Park SH; Kim K; Chung M; Moon W; Kang M; Jang K
J Ovarian Res; 2015 Feb; 8():2. PubMed ID: 25823848
[TBL] [Abstract][Full Text] [Related]
17. Role of CD44 in Chemotherapy Treatment Outcome: A Scoping Review of Clinical Studies.
Wu Z; Lu J; Loo A; Ho N; Nguyen D; Cheng PY; Mohammed AI; Cirillo N
Int J Mol Sci; 2024 Mar; 25(6):. PubMed ID: 38542115
[TBL] [Abstract][Full Text] [Related]
18. Role of CD44 and CD24 Expression on 2-years Disease Free Survival in Patients with Advanced Epithelial Ovarian Carcinoma.
Feharsal Y; Andrijono A; Singoprawiro CS; Lisnawati L; Pakasi TA; Putra AD; Kusuma F; Anggraeni TD; Erlina E; Sarwanti S; Mardhiyah T
Asian Pac J Cancer Prev; 2024 Feb; 25(2):513-519. PubMed ID: 38415537
[TBL] [Abstract][Full Text] [Related]
19. Cholesterol crystals induce mechanical trauma, inflammation, and neo-vascularization in solid cancers as in atherosclerosis.
Abela GS; Katkoori VR; Pathak DR; Bumpers HL; Leja M; Abideen ZU; Boumegouas M; Perry D; Al-Janadi A; Richard JE; Barnaba C; Meza IGM
Am Heart J Plus; 2023 Nov; 35():. PubMed ID: 37981958
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
